JP2007530525A5 - - Google Patents

Download PDF

Info

Publication number
JP2007530525A5
JP2007530525A5 JP2007504496A JP2007504496A JP2007530525A5 JP 2007530525 A5 JP2007530525 A5 JP 2007530525A5 JP 2007504496 A JP2007504496 A JP 2007504496A JP 2007504496 A JP2007504496 A JP 2007504496A JP 2007530525 A5 JP2007530525 A5 JP 2007530525A5
Authority
JP
Japan
Prior art keywords
alkyl
halo
cycloalkyl
independently
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007504496A
Other languages
English (en)
Japanese (ja)
Other versions
JP4054845B2 (ja
JP2007530525A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2005/000659 external-priority patent/WO2005092864A1/en
Publication of JP2007530525A publication Critical patent/JP2007530525A/ja
Publication of JP2007530525A5 publication Critical patent/JP2007530525A5/ja
Application granted granted Critical
Publication of JP4054845B2 publication Critical patent/JP4054845B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007504496A 2004-03-23 2005-03-11 神経変性障害の治療のためのイミダゾール化合物 Expired - Lifetime JP4054845B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55562304P 2004-03-23 2004-03-23
US60/555,623 2004-03-23
PCT/IB2005/000659 WO2005092864A1 (en) 2004-03-23 2005-03-11 Imidazole compounds for the treatment of neurodegenerative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007156459A Division JP2007291123A (ja) 2004-03-23 2007-06-13 神経変性障害の治療のためのイミダゾール化合物

Publications (3)

Publication Number Publication Date
JP2007530525A JP2007530525A (ja) 2007-11-01
JP2007530525A5 true JP2007530525A5 (cg-RX-API-DMAC7.html) 2007-12-13
JP4054845B2 JP4054845B2 (ja) 2008-03-05

Family

ID=34961257

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007504496A Expired - Lifetime JP4054845B2 (ja) 2004-03-23 2005-03-11 神経変性障害の治療のためのイミダゾール化合物
JP2007156459A Pending JP2007291123A (ja) 2004-03-23 2007-06-13 神経変性障害の治療のためのイミダゾール化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007156459A Pending JP2007291123A (ja) 2004-03-23 2007-06-13 神経変性障害の治療のためのイミダゾール化合物

Country Status (42)

Country Link
US (3) US7342118B2 (cg-RX-API-DMAC7.html)
EP (1) EP1730119B1 (cg-RX-API-DMAC7.html)
JP (2) JP4054845B2 (cg-RX-API-DMAC7.html)
KR (1) KR100814599B1 (cg-RX-API-DMAC7.html)
CN (1) CN1934091B (cg-RX-API-DMAC7.html)
AP (1) AP2379A (cg-RX-API-DMAC7.html)
AR (1) AR049875A1 (cg-RX-API-DMAC7.html)
AT (1) ATE399155T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005225635B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0509069B8 (cg-RX-API-DMAC7.html)
CA (1) CA2560580C (cg-RX-API-DMAC7.html)
CR (1) CR8644A (cg-RX-API-DMAC7.html)
CY (1) CY1108347T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005007717D1 (cg-RX-API-DMAC7.html)
DK (1) DK1730119T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2005000040A (cg-RX-API-DMAC7.html)
EA (1) EA011689B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066879A (cg-RX-API-DMAC7.html)
ES (1) ES2308441T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20084420B (cg-RX-API-DMAC7.html)
GT (1) GT200500060A (cg-RX-API-DMAC7.html)
HN (1) HN2005000115A (cg-RX-API-DMAC7.html)
HR (1) HRP20080375T3 (cg-RX-API-DMAC7.html)
IL (1) IL177594A0 (cg-RX-API-DMAC7.html)
IS (1) IS8550A (cg-RX-API-DMAC7.html)
MA (1) MA28481B1 (cg-RX-API-DMAC7.html)
NL (1) NL1028598C2 (cg-RX-API-DMAC7.html)
NO (1) NO338263B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ549331A (cg-RX-API-DMAC7.html)
PA (1) PA8627201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20051155A1 (cg-RX-API-DMAC7.html)
PL (1) PL1730119T3 (cg-RX-API-DMAC7.html)
PT (1) PT1730119E (cg-RX-API-DMAC7.html)
RS (1) RS50595B (cg-RX-API-DMAC7.html)
SI (1) SI1730119T1 (cg-RX-API-DMAC7.html)
SV (1) SV2006002055A (cg-RX-API-DMAC7.html)
TN (1) TNSN06300A1 (cg-RX-API-DMAC7.html)
TW (1) TWI372146B (cg-RX-API-DMAC7.html)
UA (1) UA83899C2 (cg-RX-API-DMAC7.html)
UY (1) UY28817A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005092864A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200606957B (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2379A (en) 2004-03-23 2012-03-08 Pfizer Prod Inc Imidazole compounds for the treatment of neurodegenerative disorders.
EP1940802A2 (en) 2005-09-22 2008-07-09 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
AU2007207743B2 (en) 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
DE102006048042A1 (de) * 2006-10-11 2008-04-17 Bayer Healthcare Ag Acylaminoimidazole und Acylaminothiazole
US8779002B2 (en) * 2007-10-15 2014-07-15 Salk Institute For Biological Studies Methods for treating a variety of diseases and conditions, and compounds useful therefor
WO2009093463A1 (ja) * 2008-01-23 2009-07-30 Taiho Pharmaceutical Co., Ltd. 神経細胞死抑制剤
EP2398771B1 (en) 2009-02-18 2015-07-29 Boehringer Ingelheim International GmbH Heterocyclic compounds which modulate the cb2 receptor
WO2010100606A1 (en) * 2009-03-03 2010-09-10 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
RU2465273C2 (ru) * 2010-08-31 2012-10-27 Общество С Ограниченной Ответственностью "Биофарм-Меморейн" ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
AU2012321345B2 (en) 2011-10-03 2016-03-17 The University Of Utah Research Foundation Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
WO2015092614A1 (en) 2013-12-20 2015-06-25 Pfizer Inc. Activating notch alterations in breast cancer
KR102000382B1 (ko) 2015-02-03 2019-07-15 화이자 인코포레이티드 신규 시클로프로파벤조푸라닐 피리도피라진디온
CA2990564A1 (en) 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic heterocyclic amide derivative
AU2016284398C1 (en) 2015-06-22 2021-01-07 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
JP6896701B2 (ja) 2016-02-26 2021-06-30 大日本住友製薬株式会社 イミダゾリルアミド誘導体
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
EP3843735A1 (en) * 2018-08-27 2021-07-07 Universiteit Maastricht Selective presenilin-2 gamma-secretase inhibitors
AU2020307471A1 (en) 2019-06-24 2022-01-27 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
US11884634B2 (en) 2019-08-09 2024-01-30 Pfizer Inc. Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
KR102772889B1 (ko) * 2019-08-09 2025-02-26 화이자 인코포레이티드 (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의 고체 상태 형태 및 이의 용도
ES3055762T3 (en) 2019-08-09 2026-02-16 Pfizer Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
KR102782229B1 (ko) * 2019-10-02 2025-03-20 (주)카이노스메드 N-(1h-이미다졸-2-일)벤즈아미드 화합물 및 활성 성분으로 이를 포함하는 약학 조성물
JP2023524854A (ja) 2020-05-13 2023-06-13 ファイザー・インク がんを処置するための方法、治療、および使用
KR20230069181A (ko) 2020-09-14 2023-05-18 화이자 인코포레이티드 암 치료를 위한 방법, 요법 및 용도
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
EP4255409A1 (en) 2020-12-07 2023-10-11 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
TW202313020A (zh) 2021-06-02 2023-04-01 瑞士商西萊絲蒂亞生物科技股份有限公司 自體免疫及發炎性疾病的治療方法
MX2024002590A (es) 2021-09-01 2024-03-22 Springworks Therapeutics Inc Sintesis de nirogacestat.
US11504354B1 (en) * 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions
WO2023079132A1 (en) 2021-11-08 2023-05-11 Cellestia Biotech Ag Pharmaceutical combinations for treating cancer
EP4436958A1 (en) * 2021-11-23 2024-10-02 Teva Pharmaceuticals International GmbH Solid state forms of nirogacestat salts
EP4223292A1 (en) 2022-02-07 2023-08-09 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
WO2023174390A1 (zh) * 2022-03-17 2023-09-21 苏州科睿思制药有限公司 尼罗司他二氢溴酸盐的晶型及其制备方法和用途
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
IL316750A (en) 2022-05-20 2025-01-01 Springworks Therapeutics Inc Treatments with Nirogesstat
US12138246B2 (en) 2022-05-20 2024-11-12 Springworks Therapeutics, Inc. Treatments with nirogacestat
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
US12667555B2 (en) 2022-05-20 2026-06-30 Springworks Therapeutics, Inc. Treatment of ovarian cancer with nirogacestat
WO2026018210A1 (en) 2024-07-19 2026-01-22 Assia Chemical Industries Ltd. Solid state forms of nirogacestat dihydrochloride salt
CN119930523B (zh) * 2025-01-22 2026-01-02 上海皓元医药股份有限公司 一种硝加司他中间体的制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US50314A (en) * 1865-10-03 Improvement in telegraph-cables
US4512A (en) * 1846-05-09 Smut-machine
DE1236426B (de) * 1960-08-25 1967-03-09 Dolomitwerke Gmbh Verfahren zur Wasseraufbereitung
US5401851A (en) 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
JPH07101958A (ja) 1992-10-16 1995-04-18 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
DE10019755A1 (de) 2000-04-20 2001-11-08 Bayer Ag Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
JP2002059707A (ja) * 2000-08-23 2002-02-26 Bridgestone Corp 空気入りタイヤ及び空気入りタイヤの製造方法
WO2002040445A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
KR101018318B1 (ko) 2001-12-21 2011-03-04 노보 노르디스크 에이/에스 Gk 활성제로서의 아미드 유도체
ES2616539T3 (es) 2002-06-05 2017-06-13 Bristol-Myers Squibb Company Antagonistas de receptores de péptidos relacionados con el gen de calcitonina
OA12937A (en) 2002-10-09 2006-10-13 Pfizer Prod Inc Thiazole compounds for the treatment of neurodegenerative disorders.
JP2006504725A (ja) 2002-10-09 2006-02-09 ファイザー・プロダクツ・インク 神経変性障害治療用ピラゾール化合物
JP2006182648A (ja) * 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7員複素環誘導体
MXPA05012196A (es) 2003-05-12 2006-02-08 Pfizer Prod Inc Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
EP1654260A4 (en) 2003-08-01 2008-09-24 Pfizer Prod Inc 6-LOW HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
MXPA06001480A (es) 2003-08-06 2006-05-15 Pfizer Prod Inc Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos.
BRPI0413709A (pt) 2003-08-21 2006-10-17 Pfizer Prod Inc compostos para o tratamento de distúrbios neurodegenerativos
US7348968B2 (en) * 2003-12-02 2008-03-25 Sony Corporation Wireless force feedback input device
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
AP2379A (en) 2004-03-23 2012-03-08 Pfizer Prod Inc Imidazole compounds for the treatment of neurodegenerative disorders.
US7232820B2 (en) 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
US7384968B2 (en) 2004-04-01 2008-06-10 Pfizer Inc. Thiazole-amine compounds for the treatment of neurodegenerative disorders
US20050222227A1 (en) 2004-04-01 2005-10-06 Pfizer Inc Oxazole-amine compounds for the treatment of neurodegenerative disorders
US7220865B2 (en) 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
US7309709B2 (en) 2004-04-01 2007-12-18 Pfizer Inc. Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
EP1940802A2 (en) * 2005-09-22 2008-07-09 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders

Similar Documents

Publication Publication Date Title
JP2009515872A5 (cg-RX-API-DMAC7.html)
JP2011508726A5 (cg-RX-API-DMAC7.html)
JP2012500805A5 (cg-RX-API-DMAC7.html)
JP2009511490A5 (cg-RX-API-DMAC7.html)
JP2005514398A5 (cg-RX-API-DMAC7.html)
JP2009502963A5 (cg-RX-API-DMAC7.html)
JP2017509689A5 (cg-RX-API-DMAC7.html)
JP2005503345A5 (cg-RX-API-DMAC7.html)
JP2009526868A5 (cg-RX-API-DMAC7.html)
JP2005298818A5 (cg-RX-API-DMAC7.html)
JP2006520397A5 (cg-RX-API-DMAC7.html)
JP2001517655A5 (cg-RX-API-DMAC7.html)
JP2007535595A5 (cg-RX-API-DMAC7.html)
JP2010532365A5 (cg-RX-API-DMAC7.html)
JP2005508961A5 (cg-RX-API-DMAC7.html)
JP2010527983A5 (cg-RX-API-DMAC7.html)
JP2007519618A5 (cg-RX-API-DMAC7.html)
BR9908074A (pt) Composto, composição farmacêutica, e, processo para fabricar um composto
JP2001524477A5 (cg-RX-API-DMAC7.html)
ATE413876T1 (de) Indolamid-derivate, die glycogen phosphorylase inhibierende aktivität besitzen
JP2008539193A5 (cg-RX-API-DMAC7.html)
JP2004525184A5 (cg-RX-API-DMAC7.html)
JP2007517826A5 (cg-RX-API-DMAC7.html)
MY118004A (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
RU2006124513A (ru) Производные бензоксазина и их применение